| P2093 | author name string | Arpita Shah | |
| P2860 | cites work | Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies | Q38142762 |
| | Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors | Q38155343 |
| | A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies | Q38474278 |
| | Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties | Q39192585 |
| | Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties | Q41966195 |
| | Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 |
| | Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab | Q46985480 |
| | A mechanism-driven treatment for chronic lymphocytic leukemia? | Q50894839 |
| | Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. | Q53962600 |
| | Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 |
| | How will B-cell-receptor-targeted therapies change future CLL therapy? | Q27024187 |
| | Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions | Q27824806 |
| | Cancer statistics, 2014 | Q27861018 |
| | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 |
| | Rituximab in chronic lymphocytic leukemia | Q33388976 |
| | U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia | Q33415277 |
| | Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups | Q33913537 |
| | The clinical application of monoclonal antibodies in chronic lymphocytic leukemia | Q34310845 |
| | Obinutuzumab: first global approval | Q34391958 |
| | Drug monographs: afatinib and obinutuzumab | Q37676327 |
| | Monoclonal antibody therapy of chronic lymphocytic leukaemia | Q37771672 |
| | Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly | Q37844139 |
| | Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis | Q38019093 |
| | Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia | Q38100787 |
| | Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment | Q38110472 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| | monoclonal antibody | Q422248 |
| | lymphocyte | Q715347 |
| | chronic lymphocytic leukemia | Q1088156 |
| P304 | page(s) | 1356-1361 | |
| P577 | publication date | 2014-07-18 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia | |
| P478 | volume | 48 | |